- Home
- DXCM vs ZTS Comparison
DXCM vs ZTS Comparison
Compare DXCM & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXCM | ZTS |
|---|---|---|
| Founded | 1999 | 1952 |
| Country | United States | United States |
| Employees | N/A | 14500 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.4B | 29.0B |
| IPO Year | 2005 | 2012 |
Fundamental Metrics
Financial Performance| Metric | DXCM | ZTS |
|---|---|---|
| Price | $86.64 | $71.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 12 |
| Target Price | $85.33 | ★ $154.18 |
| AVG Volume (30 Days) | ★ 3.3M | 3.2M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.86% |
| EPS Growth | ★ 47.18 | 10.05 |
| EPS | 1.15 | ★ 3.08 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | $14.46 | $5.63 |
| Revenue Next Year | $12.31 | $4.77 |
| P/E Ratio | $76.06 | ★ $22.83 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $54.11 | $69.93 |
| 52 Week High | $92.59 | $148.79 |
Technical Indicators
Market Signals| Indicator | DXCM | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 38.66 |
| Support Level | $82.29 | N/A |
| Resistance Level | $92.46 | $78.20 |
| Average True Range (ATR) | 2.18 | 1.58 |
| MACD | -0.15 | -0.29 |
| Stochastic Oscillator | 60.04 | 23.48 |
Price Performance
Historical ComparisonAbout DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.